Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × mCRPC × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 68 Breast Neoplasms 43 Neoplasms 26 Prostatic Neoplasms 25 Multiple Myeloma 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 19 Lung Neoplasms 19 Ovarian Neoplasms 16 Leukemia, Lymphocytic, Chronic, B-Cell 16 Myasthenia Gravis 15 Colorectal Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 14 Neoplasm Metastasis 14 Lymphoma, Follicular 14 Leukemia, Myeloid, Acute 14 Melanoma 13 Stomach Neoplasms 12 Recurrence 11 Carcinoma, Renal Cell 10 Urinary Bladder Neoplasms 9 Small Cell Lung Carcinoma 9 Non-Muscle Invasive Bladder Neoplasms 9 Glioblastoma 9 Carcinoma 9 Lymphoma, Non-Hodgkin 8 Fallopian Tube Neoplasms 8 Endometrial Neoplasms 8 Uterine Cervical Neoplasms 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma, Large B-Cell, Diffuse 7

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡